Table IV.
Association between the expression of miR-133b and clinicopathological parameters of gastric cancer.
| Variable | Cases, n (%) | Expression of miR-133b, median ± range | P-value |
|---|---|---|---|
| Gender | 0.675 | ||
| Male | 32 (57) | 8.811±0.506 | |
| Female | 24 (43) | 9.117±0.493 | |
| Age, years | 0.720 | ||
| ≤50 | 18 (32) | 8.754±0.381 | |
| >50 | 38 (68) | 9.031±0.495 | |
| Tumor size, cm | 0.606 | ||
| ≤5 | 31 (55) | 8.774±0.504 | |
| >5 | 25 (45) | 9.149±0.502 | |
| Degree of differentiation | 0.047* | ||
| Well and moderately | 17 (30) | 6.637±0.739 | |
| Poorly | 39 (70) | 9.475±0.402 | |
| TNM stage | 0.043* | ||
| I/II | 27 (48) | 6.952±0.576 | |
| III/IV | 29 (52) | 8.933±0.440 | |
| Lymph-node status | 0.025* | ||
| No metastasis | 6 (11) | 8.667±0.337 | |
| Metastasis | 50 (89) | 11.231±0.591 |
miR, microRNA; TNM, tumor node metastasis.